Following on from the news that Lutetium (177lu) oxodotreotide was recommended, today we can share with you the Final Appraisal Document for Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease.
[npfButton size=“small” text=”Find out more” href=”https://www.nice.org.uk/guidance/ta539″ background-colour=”#37b8c0″ text-colour=”#ffffff”]